The case of dolutegravir in Colombia highlights the ongoing global debate about balancing public health priorities with intellectual property rights. Faced with the challenge of providing equitable access to a critical HIV treatment, the Colombian government took bold steps that ultimately led to litigation. This document outlines the timeline, challenges, and resolution of the case, demonstrating Colombia’s commitment to public health while complying with regional legal frameworks.
Declaration of public interest and compulsory licensing
On October 2, 2023, the Colombian Ministry of Health and Social Protection, through Resolution 1579, declared the drug dolutegravir to be of public interest and subject to compulsory licensing. This decision aimed to ensure equitable access to HIV treatment, as dolutegravir is the first-line pharmacological alternative recommended by the World Health Organization (WHO) due to its few adverse effects and lower risk of developing resistance.
Legal challenges from patent holders
The implementation of this intervention has not been straightforward due to patent-related issues. The patent holders – ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer and Shionogi – filed appeals against the compulsory licensing of dolutegravir.
On December 1, 2023, World AIDS Day, the Ministry issued three resolutions rejecting the arguments presented in the appeals. These resolutions allowed the Superintendency of Industry and Commerce (SIC) to begin the process of granting the requested license.
Petition to the Secretariat of the Andean Community
After the SIC approved the request, in August 2024, the patent holders filed a petition with the General Secretariat of the Andean Community (SGCAN). They argued that the measure did not comply with Colombia’s obligations under the regional intellectual property framework, claiming that it failed to establish “the temporary parameters for its application”.
Resolution of the Dispute
On November 6, 2024, the SGCAN resolved the dispute and ruled in favor of Colombia. It found that Colombia had not violated its intellectual property obligations. The generic version of the retroviral drug dolutegravir would be used to meet the needs of the priority population.
The SGCAN acknowledged that the decision was aimed at controlling the increasing number of new HIV cases and facilitating access to treatment. It also stated that Colombia was not in breach of its obligations regarding the duration of the measure, as it was not possible to determine its duration in advance. The duration of the measure would depend on its social impact, in particular on the target population it was intended to benefit.
Conclusion
The SGCAN ruling reaffirmed Colombia’s commitment to public health while upholding its obligations under regional intellectual property law. By prioritizing the needs of vulnerable populations and ensuring equitable access to life-saving treatments, Colombia has set an important precedent for balancing public health imperatives with intellectual property rights.
